Iovance Biotherapeutics (IOVA) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Iovance Biotherapeutics (IOVA) over the last 14 years, with Q3 2025 value amounting to -$300.8 million.
- Iovance Biotherapeutics' Enterprise Value fell 8322.76% to -$300.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$300.8 million, marking a year-over-year decrease of 8322.76%. This contributed to the annual value of -$323.8 million for FY2024, which is 1569.1% down from last year.
- Iovance Biotherapeutics' Enterprise Value amounted to -$300.8 million in Q3 2025, which was down 8322.76% from -$301.2 million recorded in Q2 2025.
- In the past 5 years, Iovance Biotherapeutics' Enterprise Value ranged from a high of -$164.2 million in Q3 2024 and a low of -$626.3 million during Q1 2023
- For the 3-year period, Iovance Biotherapeutics' Enterprise Value averaged around -$323.0 million, with its median value being -$301.2 million (2025).
- Per our database at Business Quant, Iovance Biotherapeutics' Enterprise Value skyrocketed by 5457.2% in 2024 and then tumbled by 8322.76% in 2025.
- Iovance Biotherapeutics' Enterprise Value (Quarter) stood at -$279.9 million in 2023, then fell by 15.69% to -$323.8 million in 2024, then increased by 7.09% to -$300.8 million in 2025.
- Its Enterprise Value stands at -$300.8 million for Q3 2025, versus -$301.2 million for Q2 2025 and -$359.7 million for Q1 2025.